Human HER-2/neu protein immunization circumvents tolerance to rat neu: A vaccine strategy for 'self' tumour antigens

Immunology

Volumn 93, Issue 2, 1998, Pages 192-199

  Disis, M L ^a   Shiota, F M ^a   Cheever, M A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PROTEIN P53; TUMOR ANTIGEN; VACCINE;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; VACCINATION;

EID: 0031932303     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1998.00424.x     Document Type: Article

References (27)

1. HOUGHTON A.N. (1994) Cancer antigens: immune recognition of self and altered self [comment]. J Exp Med 180, 1.
2. NANDA N.K. & SERCARZ E.E. (1995) Induction of anti-self-immunity to cure cancer. Cell 82, 13.
3. KAWAKAMI Y., ELIYAHU S., SAKAGUCHI K. et al. (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 180, 347.
4. GAUGLER B., VAN-DEN-EYNDE B., VAN-DER-BRUGGEN P. et al. (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179, 921.
5. BAKKER A.B., SCHREURS M.W., DE-BOER A.J. et al. (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179, 1005.
6. DISIS M. & CHEEVER M. (1996) Oncogenic proteins as tumor antigens. Curr Opin Immunol (8)5, 637.
7. BEN-MAHREZ K., SOROKINE I., THIERRY D., KAWASUMI T., ISHII S., SALMON R. & KOHIYAMA M. (1990) Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 46, 35.
8. SCHLICHTHOLZ B., LEGROS Y., GILLET D. et al. (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52, 6380.
9. TAKAHASHI M., CHEN W., BYRD D. et al. (1995) Antibody responses to ras proteins in patients with colon cancer. Clin Cancer Res. Advances in Brief 1, 1071.
10. YONEMURA Y., NINOMIYA I., YAMAGUCHI A. et al. (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 51, 1034.
11. BERCHUCK A., KAMEL A., WHITAKER R. et al. (1990) Overexpression of HER-2 neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50, 4087.
12. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50, 5184.
13. SLAMON D., CLARK G., WONG S., LEVIN W., ULLRICH A. & MCGUIRE W. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177.
14. GUSTERSON B., GELBER R., GOLDHIRSCH A. et al. (1992) Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10, 1049.
15. BERNARDS R., DESTREE A., MCKENZIE S., GORDON E., WEINBERG R.A. & PANICALI D. (1987) Effective tumor immunotherapy directed against an oncogene-encoded product using a vacinnia virus vector. Proc Natl Acad Sci USA 84, 6854.
16. DISIS M.L., GRALOW J.R., BERNHARD H., HAND S.L., RUBIN W.D. & CHEEVER M.A. (1996) Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self-protein. J Immunol 156, 3151.
17. MAMULA M.J., LIN R.H., JANEWAY C.A., JR. & HARDIN J.A. (1992) Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c. J Immunol 149, 789.
18. DISIS M. & CHEEVER M. (1997) HER-2/neu protein: a target for antigen specific immunotherapy of human cancer. Adv Cancer Res 71, 343.
19. FISK B., BLEVINS T.L., WHARTON J.T. & IOANNIDES C.G. (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181, 2109.
20. PEOPLES G.E., GOEDEGEBUURE P.S., SMITH R., LINEHAN D.C., YOSMINO I. & EBERLEIN T.J. (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2 neu-derived peptide. Proc Natl Acad Sci USA 92, 432.
21. DISIS M.L., CALENOFF E., MCLAUGHLIN G. et al. (1994) Existent T cell and antibody immunity to HER-2 neu protein in patients with breast cancer. Cancer Res 54, 16.
22. KATSUMATA M., OKUDAIRA T., SAMANTA A. et al. (1995) Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1, 644.
23. BASELGA J., TRIPATHY D., MENDELSOHN J. et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2 neu-overexpressing metastatic breast cancer [see comments]. J Clin Oncol 14, 737.
24. SKINNER S.M., KILLIAN G.J., MILLER L.A. & DUNBAR B.S. (1994) Characterization of antigenicity and immunogenicity patterns of native and recombinant zona pellucida proteins in the white-tailed deer (Oidocoileus virginianus). J Reprod Fertil 101, 295.
25. MAHI-BROWN C.A., MCGUINNESS R.P. & MORAN F. (1992) The cellular immune response to immunization with zona pellucida antigens. J Reprod Immunol 21, 29.
26. MAMULA M.J. (1993) The inability to process a self-peptide allows autoreactive T cells to escape tolerance. J Exp Med 177, 567.
27. CHEEVER M., GREENBERG P. & FEFER A. (1981) Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with interleukin-2. J Immunol 126, 1318.